Venclyxto (venetoclax)

Venclyxto (venetoclax) is available by a medical need program since 1-04-2017 for the following indications:

1. Treatment CLL in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.
2. Treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor. 

All information can be found in the file of the MNP products